Anders Österborg

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

Medicine, Oncology, Chemotherapy +11

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

William G. Wierda, Thomas J. Kipps, Stephan Stilgenbauer et al. · Journal of Clinical Oncology · 2010 · 587 citations

Pharmacy, Oncology, Pharmacotherapy +17

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm et al. · Blood · 2002 · 499 citations · Full text

Medicine, Hematology, Oncology +16

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials

Stefano Pasquali, J D Maqueo, Jorge Espino Vela et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1998 · 473 citations

Medicine, Oncology, Pharmacology +16

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen et al. · New England Journal of Medicine · 2022 · 457 citations · Full text

Medicine, Oncology, Pharmacology +16